Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Parulekar

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Oral Oncology|July 11, 1998
Scoring oral mucositisW Parulekar, R Mackenzie, G Bjarnason, et al.
Chest|July 14, 2001
Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusionsW Parulekar, G Di Primio, F Matzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2024
Reply to 'Letter to the Editor regarding "Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial [NCT00541047]", by C. C. Parker et al.'C C Parker, C N Catton, N Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2003
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and painD S Ernst, I F Tannock, E W Winquist, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placeboM M Vickers, E D Powell, T R Asmis, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 16, 2007
RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery)C Parker, N Clarke, J Logue, et al.
NPJ Breast Cancer|August 29, 2025
Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional node radiotherapy trialN Riaz, B E Chen, A Bane, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 7, 2005
Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 studyM Mason, P Warde, M Sydes, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|September 8, 2016
Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3M M Vickers, C Lee, D Tu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2023
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancerW Xie, P Ravi, M Buyse, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Oral Oncology|July 11, 1998
Scoring oral mucositisW Parulekar, R Mackenzie, G Bjarnason, et al.
Chest|July 14, 2001
Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusionsW Parulekar, G Di Primio, F Matzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2024
Reply to 'Letter to the Editor regarding "Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial [NCT00541047]", by C. C. Parker et al.'C C Parker, C N Catton, N Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2003
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and painD S Ernst, I F Tannock, E W Winquist, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placeboM M Vickers, E D Powell, T R Asmis, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 16, 2007
RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery)C Parker, N Clarke, J Logue, et al.
NPJ Breast Cancer|August 29, 2025
Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional node radiotherapy trialN Riaz, B E Chen, A Bane, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 7, 2005
Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 studyM Mason, P Warde, M Sydes, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|September 8, 2016
Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3M M Vickers, C Lee, D Tu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2023
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancerW Xie, P Ravi, M Buyse, et al.
Pageof 2